Definium Therapeutics Target of Unusually Large Options Trading (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) saw unusually large options trading on Friday. Stock investors purchased 9,041 call options on the stock. This is an increase of approximately 292% compared to the typical daily volume of 2,306 call options.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the transaction, the insider owned 320,571 shares of the company’s stock, valued at $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This represents a 2.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 48,096 shares of company stock valued at $2,165,763 in the last 90 days. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its stake in Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares in the last quarter. Creative Planning grew its position in shares of Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Definium Therapeutics by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after buying an additional 2,342 shares during the last quarter. Rhumbline Advisers increased its position in Definium Therapeutics by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after purchasing an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX traded down $1.38 on Friday, reaching $47.07. 2,555,622 shares of the company were exchanged, compared to its average volume of 4,602,458. The company has a 50-day moving average of $29.22 and a 200-day moving average of $21.67. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm has a market cap of $4.69 billion, a price-to-earnings ratio of -18.90 and a beta of 2.20. Definium Therapeutics has a 1-year low of $7.76 and a 1-year high of $49.20.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities analysts forecast that Definium Therapeutics will post -2.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DFTX shares. Robert W. Baird lifted their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. Needham & Company LLC increased their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. JonesTrading raised their price objective on shares of Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $49.23.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.